Patents Assigned to The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services
-
Patent number: 7709626Abstract: This application provides universal labeled primers for detection and amplification of nucleic acid molecules. These universal primers can be attached to the 5?-end of a target sequence-specific primer. In particular examples, the universal primer includes a labeled nucleotide flanked on both sides a nucleotide whose complement nucleotides changes a detectable signal from the label when the universal primer hybridizes with its complementary nucleic acid molecule. Also disclosed are methods of using the universal primer in nucleic acid amplification, such as real-time PCR.Type: GrantFiled: November 10, 2008Date of Patent: May 4, 2010Assignee: The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and PreventionInventors: Jothikumar Narayanan, Vincent Hill
-
Patent number: 7695752Abstract: A device for performing target activated transfer that includes a mounting surface for mounting a tissue sample; and a light source positioned to substantially uniformly irradiate both stained and unstained regions of the tissue sample with light energy that activates the reagent to selectively adhere the stained regions to a transfer surface. Also described is an automated system for transferring tissue from a tissue sample to a transfer substrate. The system includes means for holding a tissue section that includes targets specifically stained with an absorptive stain thereby resulting in a stained tissue surface, and a flexible transfer film that includes a lower thermoplastic layer in sufficient thermal contact with the stained tissue surface; an irradiating assembly configured to provide a predetermined uniform light dose to the entire tissue section; and means for applying a constant pressure to the transfer film during irradiation.Type: GrantFiled: August 12, 2005Date of Patent: April 13, 2010Assignee: The Government of the United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Robert F. Bonner, Thomas J. Pohida, Michael R. Emmert-Buck, Michael Anthony Tangrea, Rodrigo F. Chuaqui
-
Patent number: 7691386Abstract: The present invention provides a papillomavirus-like particle, characterized as having conformational epitopes, comprising a papillomavirus L1 product and a papillomavirus L2 fusion product; and related synthetic DNA molecules, host cells, methods and vaccines.Type: GrantFiled: December 9, 2008Date of Patent: April 6, 2010Assignee: The Government of the United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Douglas R. Lowy, John T. Schiller, Heather Greenstone
-
Patent number: 7493854Abstract: The present disclosure concerns a jam detection and safety system for machines prone to jamming, such as a baler. In particular embodiments, the system is implemented in a horizontal baler having a shear bar and a hydraulic ram that advances material being baled past the shear bar into a compression chamber. The system includes a strain gage mounted on the shear bar and a controller that is electrically connected to the strain gage. The controller receives strain signals from the stage gage and compares the strain of the shear bar to a predetermined strain threshold corresponding to a jamming condition. If the strain exceeds the predetermined threshold, the controller automatically deactivates the ram, such as by disconnecting line power from the baler and/or by turning off the control power of the baler.Type: GrantFiled: November 6, 2006Date of Patent: February 24, 2009Assignees: The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services, West Virginia UniversityInventors: John R. Etherton, John R. Powers, Jr., Eugene Anthony McKenzie, Jr., Kenneth Means, Brad Newbraugh
-
Patent number: 7320881Abstract: Provided are Nocardia farcinica-specific primers comprising the nucleotide sequence of SEQ ID NO:1-39. Provided is a polynucleotide represented by SEQ ID NO:41 and SEQ ID NO:40. Further provided is a method of identifying a Nocardia farcinica infection in a subject with the primer identified by SEQ ID NO:1-39, or detecting the presence of a polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO:40 or SEQ ID NO:41. Also provided is a method of identifying Nocardia farcinica infection in a subject by amplifying DNA from the subject using a Nocardia farcinica-specific primer comprising a nucleotide sequence selected from the group consisting of SEQ ID NO:1-39. Further provided is a kit for identifying Nocardia farcinica comprising a Nocardia farcinica-specific primer comprising SEQ ID: NO:1-39 and a kit for identifying Nocardia farcinica comprising a Nocardia farcinica specific primer capable of amplifying SEQ ID NO:41.Type: GrantFiled: April 6, 2005Date of Patent: January 22, 2008Assignee: The Government of the United States of America as Represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and PreventionInventors: Brent A. Lasker, June M. Brown
-
Patent number: 7311916Abstract: The present invention is directed to the induction and characterization of a humoral immune response targeting “entry-relevant” gp41 structures. In its broadest aspect, the present invention is directed to methods of raising a neutralizing antibody response to a broad spectrum of HIV strains and isolates. The present invention targets particular molecular conformations or structures that occur at the cell surface of HIV during viral entry into host cells. Such a humoral response can be generated in vivo as a prophylactic measure in individuals to reduce or inhibit the ability of HIV to infect uninfected cells in the individual's body. Such a response can also be employed to raise antibodies against “entry relevant” gp41 structures. These antibodies can be employed for therapeutic uses, and as tools for further illuminating the mechanism of HIV cell entry.Type: GrantFiled: September 10, 2003Date of Patent: December 25, 2007Assignees: The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services, Panacos Pharmaceuticals, Inc.Inventors: Carl T. Wild, Carol D. Weiss
-
Patent number: 7303754Abstract: The invention provides modified virus Ankara (MVA), a replication-deficient strain of vaccinia virus, expressing human immunodeficiency virus (HIV) env, gag, and pol genes.Type: GrantFiled: September 28, 2005Date of Patent: December 4, 2007Assignees: The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services, Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The United States of America, as represented by the Secretary, Department of the ArmyInventors: Bernard Moss, Patricia L. Earl, Linda Wyatt, Leigh Anne Eller, Thomas C. VanCott, Matthew Edward Harris
-
Patent number: 7303751Abstract: Compositions that inhibit the binding of Plasmodium falciparum to erythrocytes include a family of erythrocyte binding proteins (EBPs). The EBPs are paralogues of the P. falciparum binding protein EBA-175. The present invention includes peptides of the paralogues that prevent the binding of P. falciparum. Antibodies specific for each paralogue that also prevent the binding of P. falciparum are also included. Methods of the invention utilize the paralogues, antibodies thereof and peptide compositions for the diagnosis, prevention, and treatment of P. falciparum diseases such as malaria, as well as methods for the detection of P. falciparum in biological samples and culture media.Type: GrantFiled: July 29, 2003Date of Patent: December 4, 2007Assignee: The Government of the United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: David L. Narum, Kim L. Sim
-
Patent number: 7297493Abstract: A novel gene designated as FRAG1 from and its encoded protein is disclosed. A fusion protein called FGFR2-ROS, which is formed by chromosomal rearrangement of rat FRAG1 with FGFR2 is also disclosed. Methods of producing FRAG1 protein, related fusion proteins, and antibodies against FRAG1 are disclosed, as are related pharmaceuticals and methods of using such nucleic acids, polypeptides, and antibodies are also disclosed.Type: GrantFiled: November 18, 2004Date of Patent: November 20, 2007Assignee: The Government of the United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Matthew V. Lorenzi, Toru Miki
-
Patent number: 7267941Abstract: The present invention provides variants of cyanovirin-N and water-soluble polymer conjugates thereof. The cyanovirin-N of the invention are particularly suited for site-selective covalent attachment of one or more water soluble polymers, to provide polymer conjugates of cyanovirin-N variants exhibiting antiviral activity.Type: GrantFiled: December 18, 2003Date of Patent: September 11, 2007Assignees: The Government of the United States of America as represented by The Secretary of The Department of Health and Human Services, The National Institutes of Health, Nektar Therapeutics ALInventors: M. Elizabeth Snell, Michael J. Roberts, Toshiyuki Mori, Barry R. O'Keefe, Michael R. Boyd
-
Patent number: 7235365Abstract: A specific binding agent is provided, wherein the specific binding agent specifically binds Kaposi's sarcoma-associated herpesvirus (KSHV) interleukin-6 (vIL-6), and the specific binding agent neutralizes an activity of vIL-6. In one embodiment, the specific binding agent is an antibody. Methods are provided for using a specific binding agent that binds vIL-6, and neutralizes a biological activity of vIL-6. Methods of treatment for a KSHV-associated disorder are also provided. Methods for diagnosing a KSHV-associated disorder are provided, as are kits that include a specific binding agent of the invention. A method is also provided for testing an agent for effectiveness in treating a KSHV-associated disorder. The method includes incubating the agent with a cell free system comprising a vIL-6 receptor component and vIL-6, and comparing the binding of vIL-6 and the receptor component in the presence of the agent to binding of vIL-6 to the receptor component in the absence of the agent.Type: GrantFiled: July 25, 2006Date of Patent: June 26, 2007Assignee: The Government of the United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Yoshiyasu Aoki, Giovanna Tosato
-
Patent number: 7235232Abstract: Hybrid human interferon-? polypeptides, and the corresponding nucleic acid molecules, are disclosed. Pharmaceutical compositions comprising these peptides, and the use of these polypeptides to treat viral disease and regulate cell growth are also provided.Type: GrantFiled: July 8, 2003Date of Patent: June 26, 2007Assignee: The Government of the United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Kathryn C. Zoon, Renqiu Hu, Joseph B. Bekisz, Mark P. Hayes
-
Patent number: 7052836Abstract: Nucleic acids for detecting Aspergillus species and other filamentous fungi are provided. Unique internal transcribed space 2 coding regions permit the development of nucleic acid probes specific for five different species of Aspergillus, three species of Fusarium, four species of Mucor, two species of Penecillium, five species of Rhizopus, one species of Rhizomucor, as well as probes for Absidia corymbifer, Cunninghamella elagans, Pseudallescheria boydii, and Sporothrix schenkii. Methods are disclosed for the species-specific detection and diagnosis of infection by Aspergillus, Fusarium, Mucor, Penecillium, Rhizomucor, absidia, Cunninghaemella, Pseudallescheria or Sporthrix in a subject. Furthermore, genus-specific probes are also provided for Aspergillus, Fusarium and Mucor, in addition to an all-fungus nucleic acid probe.Type: GrantFiled: January 14, 2002Date of Patent: May 30, 2006Assignee: The Government of the United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Christine J. Morrison, Errol Reiss, Jong Soo Choi, Liliana Aidorevich
-
Patent number: 7045132Abstract: The invention provides a nucleic acid encoding the 37-kDa protein from Streptococcus pneumoniae. Also provided are isolated nucleic acids comprising a unique fragment of at least 10 nucleotides of the 37-kDa protein. The invention also provides purified polypeptides encoded by the nucleic acid encoding the 37-kDa protein from and the nucleic acids comprising a unique fragment of at least 10 nucleotides of the 37-kDa protein. Also provided are antibodies which selectively binds the polypeptides encoded by the nucleic acid encoding the 37-kDa protein and the nucleic acids comprising a unique fragment of at least 10 nucleotides of the 37-kDa protein. Also provided are vaccines comprising immunogenic polypeptides encoded by the nucleic acid encoding the 37-kDa protein and the nucleic acids comprising a unique fragment of at least 10 nucleotides of the 37-kDa protein.Type: GrantFiled: June 4, 2003Date of Patent: May 16, 2006Assignee: The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services, c/o Centers for Disease Control and PreventionInventors: Jacquelyn Sampson, Harold Russell, Jean A. Tharpe, Edwin W. Ades, George M. Carlone
-
Patent number: 5928670Abstract: An intrinsic aldose reductase inhibitor is isolated and purified from mammalian cells, such as rat or human kidney cells. The intrinsic aldose reductase inhibitor may be incorporated into pharmaceutical compositions for the treatment of certain conditions related to diabetes.Type: GrantFiled: November 26, 1997Date of Patent: July 27, 1999Assignee: The Government of the United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Peter F. Kador, Yukio Takahashi, Tomoyuki Terada, Libaniel Rodriguez, Matteo Schaffhauser
-
Patent number: 5733548Abstract: Immunogenic chimeric proteins comprising an endoplasmic reticulum signal sequence and at least one other peptide are disclosed. The invention relates to the design of vaccinia virus constructs capable of directing host organism synthesis of immunogenic chimeric proteins which can be used as immunogens, as vaccines, or in methods of treatment for cancer, infectious diseases, or autoimmune diseases.Type: GrantFiled: June 5, 1995Date of Patent: March 31, 1998Assignee: The Government of the United States of America, as represented by the Secretary of the Department of Health and Human ServicesInventors: Nicholas P. Restifo, Steven A. Rosenberg, Jack R. Bennink, Igor Bacik, Jonathan W. Yewdell
-
Patent number: 5641487Abstract: The present invention relates to contraceptive vaccines based on cloned zona pellucida genes and the strategy of alloimmunization with zona pellucida polypeptides. In particular, the present invention relates to a contraceptive vaccine for use in a mammalian female comprising a polypeptide which displays at least one epitope for binding of an antibody that inhibits fertilization of an oocyte by a sperm. This epitope is from a zona pellucida protein of the species in which the said vaccine is used. This invention relates, more particularly, to such vaccines wherein the zona pellucida protein is the ZP3 protein or the mouse or homologues of the protein in some other mammalian species. Further, this invention comprehends vaccines comprising a synthetic peptide that displays an epitope for such an antibody that inhibits fertilization. In addition, this invention relates to cloned DNA segments variously encoding the mouse ZP3 protein or the human ZP3 protein.Type: GrantFiled: March 26, 1993Date of Patent: June 24, 1997Assignee: The Government of the United States of America as represented by the Secretary Department of Health and Human ServicesInventor: Jurrien Dean
-
Patent number: 5604093Abstract: A new human B lymphotropic virus, also designated human herpesvirus-6, has been isolated. DNA, molecular clones, antigenic viral proteins and antibodies having specificity to the new virus have been prepared. Various utilities of the new virus and products derived therefrom have been described.Type: GrantFiled: February 22, 1995Date of Patent: February 18, 1997Assignee: The Government of the United States of America, as represented by the Secretary of the Department of Health and Human ServicesInventors: Syed Z. Salahuddin, Dharam V. Ablashi, Steven F. Josephs, Carl W. Saxinger, Flossie Wong-Staal, Robert C. Gallo
-
Irradiance attachment for an optical fiber to provide a uniform level of illumination across a plane
Patent number: 5519534Abstract: A irradiation attachment for an optical fiber which provides an output of light that has a highly uniform intensity. The device includes a hollow spherical shell having a diffusive reflective surface or target supported therein. Light is directed into the hollow spherical shell so that it reflects off the diffusive reflective surface or target. The reflected light is internally reflected off the inner surface of the hollow spherical shell several times before passing through an output aperture. As a result of the internal reflection within the hollow spherical shell, the light leaving the device has a highly uniform intensity. The device is particularly useful for photodynamic therapy.Type: GrantFiled: May 25, 1994Date of Patent: May 21, 1996Assignee: The Government of the United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Paul D. Smith, John Cole, Frank Harrington, Eric F. Bernstein -
Patent number: 5468610Abstract: The invention relates to polymorphic markers (two tetranucleotide and one dinucleotide repeat polymorphisms) that are useful for human individualization. Applications are in forensic medicine and for paternity and prenatal screening as well as genetic mapping. These markers are characterized by sets of oligonucleotide primers according to the invention useful in PCR amplification and DNA segment resolution. The invention further relates to an assay for measuring the subtle differences in genetic material regarding an added or omitted set of dinucleotide or tetranucleotide repeat polymorphisms which comprises obtaining an amount of nucleotide segments effective for testing, amplifying the segments by the PCR procedure using at least one primer nucleotide sequence according to the present invention, resolving the amplified segments using gel electrophoresis, and comparing the resolved segments by autoradiography to observe the differences in migration patterns due to structural differences.Type: GrantFiled: June 9, 1993Date of Patent: November 21, 1995Assignee: The Government of the United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Mihael H. Polymeropoulos, Carl R. Merril